Patents by Inventor Stephen Trulli

Stephen Trulli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel Integrin Ligand ITGL-TSP
    Publication number: 20070027084
    Abstract: ITGL-TSP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ITGL-TSP polypeptides and polynucleotides in the design of protocols for the treatment of, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retmopathy), restenosis, Alzheimer's disease and tissue remodeling, among others, and diagnostic assays for such conditions.
    Type: Application
    Filed: September 28, 2006
    Publication date: February 1, 2007
    Applicants: Human Genome Sciences, Inc., SmithKline Beecham Corp.
    Inventors: Zdenka Jonak, Stephen Trulli, James Fornwald, Jonathon Terrett, Gregg Hastings
  • Novel Integrin Ligand ITGL-TSP
    Publication number: 20070026495
    Abstract: ITGL-TSP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ITGL-TSP polypeptides and polynucleotides in the design of protocols for the treatment of, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retmopathy), restenosis, Alzheimer's disease and tissue remodeling, among others, and diagnostic assays for such conditions.
    Type: Application
    Filed: September 28, 2006
    Publication date: February 1, 2007
    Applicants: Human Genome Sciences, Inc., SmithKline Beecham Corp.
    Inventors: Zdenka Jonak, Stephen Trulli, James Fornwald, Jonathan Terrett, Gregg Hastings
  • Novel integrin ligand ITGL-TSP
    Publication number: 20050208618
    Abstract: ITGL-TSP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed Also disclosed are methods for utilizing ITGL-TSP polypeptides and polynucleotides in the design of protocols for the treatment of, angiogenic diseases (cancer, cancer metasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retinopathy), restenosis, Alzheimer's disease and tissue remodeling, among others, and diagnostic assays for such conditions.
    Type: Application
    Filed: January 15, 2004
    Publication date: September 22, 2005
    Applicants: Human Genome Sciences, Inc., SmithKline Beecham Corp.
    Inventors: Zdenka Jonak, Stephen Trulli, James Fornwald, Jonathon Terrett, Gregg Hastings
  • Human lymphoid cells expressing human immunodeficiency virus envelope protein gp160
    Patent number: 5580720
    Abstract: The present invention provides mammalian cells modified to stably express at least the entire human immunodeficiency virus-1 envelope protein gp160. The invention provides a vaccine comprising the cells of the invention. The invention also provides methods for screening compounds for their ability to inhibit formation of syncytia between cells that express HIV-1 gp160 and cells that express CD4 comprising mixing cells of invention, cells that express CD4 on their surfaces, and a test compound for a length of time sufficient for syncytia to form; and then determining the amount of syncytia formation.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 3, 1996
    Assignee: SmithKline Beecham Corporation
    Inventors: Zdenka L. Jonak, Christine Debouck, Robert Clark, Stephen Trulli
  • Human lymphoid cells expressing human immunodeficiency virus envelope protein GP160
    Patent number: 5462872
    Abstract: The present invention provides mammalian cells modified to stably express at least the entire human immunodeficiency virus-1 envelope protein gp160. The invention provides a vaccine comprising the cells of the invention. The invention also provides methods for screening compounds for their ability to inhibit formation of syncytia between cells that express HIV-1 gp160 and cells that express CD4 comprising mixing cells of invention, cells that express CD4 on their surfaces, and a test compound for a length of time sufficient for syncytia to form; and then determining the amount of syncytia formation.
    Type: Grant
    Filed: October 8, 1993
    Date of Patent: October 31, 1995
    Assignee: SmithKline Beecham Corporation
    Inventors: Zdenka L. Jonak, Christine Debouck, Robert Clark, Stephen Trulli